Immunotherapy versus chemotherapy as adjuvant therapy for resected MSI-H/dMMR colorectal cancer: real-world evidence informing precision strategies
BackgroundImmunotherapy has demonstrated unique advantages in MSI-H/dMMR colorectal cancer (CRC) for its later-line, first-line in metastatic status, and neoadjuvant therapy. However, evidence regarding its value in postoperative adjuvant therapy rem…